| Literature DB >> 32804079 |
Lu Lv1,2, Peihao Chen2,3, Longzhi Cao2,4, Yamei Li2,4, Zhi Zeng2,4, Yue Cui1,2, Qingcui Wu2, Jiaojiao Li2, Jian-Hua Wang2, Meng-Qiu Dong2,5, Xiangbing Qi2,5, Ting Han2,4,5.
Abstract
Molecular-glue degraders mediate interactions between target proteins and components of the ubiquitin-proteasome system to cause selective protein degradation. Here, we report a new molecular glue HQ461 discovered by high-throughput screening. Using loss-of-function and gain-of-function genetic screening in human cancer cells followed by biochemical reconstitution, we show that HQ461 acts by promoting an interaction between CDK12 and DDB1-CUL4-RBX1 E3 ubiquitin ligase, leading to polyubiquitination and degradation of CDK12-interacting protein Cyclin K (CCNK). Degradation of CCNK mediated by HQ461 compromised CDK12 function, leading to reduced phosphorylation of a CDK12 substrate, downregulation of DNA damage response genes, and cell death. Structure-activity relationship analysis of HQ461 revealed the importance of a 5-methylthiazol-2-amine pharmacophore and resulted in an HQ461 derivate with improved potency. Our studies reveal a new molecular glue that recruits its target protein directly to DDB1 to bypass the requirement of a substrate-specific receptor, presenting a new strategy for targeted protein degradation.Entities:
Keywords: CDK12/CCNK; biochemistry; chemical biology; human; molecular glue; target identification; targeted protein degradation
Mesh:
Substances:
Year: 2020 PMID: 32804079 PMCID: PMC7462607 DOI: 10.7554/eLife.59994
Source DB: PubMed Journal: Elife ISSN: 2050-084X Impact factor: 8.140